nach oben

11.03.2024 | Main topic

The new ESC acute coronary syndrome guideline and its impact in the CPU and emergency department setting

verfasst von: Univ.-Prof. Dr. med. Martin Möckel, FESC, FAHA

Erschienen in: Herz

Einloggen, um Zugang zu erhalten

Abstract

The new guideline on acute coronary syndrome (ACS) of the European Society of Cardiology (ESC) replaces two separate guidelines on ST-elevation myocardial infarction (STEMI) and non-ST-elevation (NSTE) ACS. This change of paradigm reflects the experts view that the ACS is a continuum, starting with unstable angina and ending in cardiogenic shock or cardiac arrest due to severe myocardial ischemia. Secondary, partly non-atherosclerotic-caused myocardial infarctions (“type 2”) are not integrated in this concept.

With respect to acute care in the setting of emergency medicine and the chest pain unit structures, the following new aspects have to be taken into account:

1. New procedural approach as “think A.C.S.” meaning “abnormal ECG,” “clinical context,” and “stable patient”

2. New recommendation regarding a holistic approach for frail patients

3. Revised recommendations regarding imaging and timing of invasive strategy in suspected NSTE-ACS

4. Revised recommendations for antiplatelet and anticoagulant therapy in STEMI

5. Revised recommendations for cardiac arrest and out-of-hospital cardiac arrest

6. Revised recommendations for in-hospital management (starting in the CPU/ED) and ACS comorbid conditions

In summary, the changes are mostly gradual and are not based on extensive new evidence, but more on focused and healthcare process-related considerations.

Byrne RA, Rossello X, Coughlan JJ et al (2023) 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 44(38):3720–3826CrossRefPubMed

Apple FS, Wu AH, Mair J et al (2005) Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51(5):810–824CrossRefPubMed

Searle J, Danne O, Müller C, Mockel M (2011) Biomarkers in acute coronary syndrome and percutaneous coronary intervention. Minerva Cardioangiol 59(3):203–223PubMed

Collet JP, Thiele H, Barbato E et al (2021) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42(14):1289–1367CrossRefPubMed

Giannitsis E, Blankenberg S, Christenson RH et al (2021) Critical appraisal of the 2020 ESC guideline recommendations on diagnosis and risk assessment in patients with suspected non-ST-segment elevation acute coronary syndrome. Clin Res Cardiol 110(9):1353–1368CrossRefPubMedPubMedCentral

Chung K, Wilkinson C, Veerasamy M, Kunadian V (2021) Frailty scores and their utility in older patients with cardiovascular disease. Interv Cardiol 16:e5CrossRefPubMedPubMedCentral

Rockwood K, Song X, MacKnight C et al (2005) A global clinical measure of fitness and frailty in elderly people. Cmaj 173(5):489–495CrossRefPubMedPubMedCentral

Ekerstad N, Pettersson S, Alexander K et al (2018) Frailty as an instrument for evaluation of elderly patients with non-ST-segment elevation myocardial infarction: a follow-up after more than 5 years. Eur J Prev Cardiol 25(17):1813–1821CrossRefPubMed

Yoshioka N, Takagi K, Morita Y et al (2019) Impact of the clinical frailty scale on mid-term mortality in patients with ST-elevated myocardial infarction. Int J Cardiol Heart Vasc 22:192–198PubMedPubMedCentral

10.

Lee KK, Bularga A, O’Brien R et al (2021) Troponin-guided coronary computed tomographic angiography after exclusion of myocardial infarction. J Am Coll Cardiol 78(14):1407–1417CrossRefPubMedPubMedCentral

11.

Thygesen K, Alpert JS, Jaffe AS et al (2019) Fourth universal definition of myocardial infarction (2018). Eur Heart J 40(3):237–269CrossRefPubMed

12.

Giannitsis E, Garfias-Veitl T, Slagman A et al (2022) Biomarkers-in-cardiology 8 RE-VISITED-consistent safety of early discharge with a dual marker strategy combining a normal hs-cTnT with a normal copeptin in low-to-intermediate risk patients with suspected acute coronary syndrome—a secondary analysis of the randomized biomarkers-in-cardiology 8 trial. Cells 11(2)

13.

Lindner T, Slagman A, Senkin A et al (2015) Medical history of elderly patients in the emergency setting: not an easy point-of-care diagnostic marker. Emerg Med Int 2015:490947CrossRefPubMedPubMedCentral

14.

Möckel M, Searle J, Hamm C et al (2015) Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 36(6):369–376CrossRefPubMed

15.

Riedlinger D, Möckel M, Müller C et al (2018) High-sensitivity cardiac troponin T for diagnosis of NSTEMI in the elderly emergency department patient: a clinical cohort study. Biomarkers 23(6):551–557CrossRefPubMed

16.

Searle J, Slagman A, Stockburger M et al (2015) Use of copeptin in emergency patients with cardiac chief complaints. Eur Heart J Acute Cardiovasc Care 4(5):393–402CrossRefPubMed

17.

Slagman A, Searle J, Müller C, Möckel M (2015) Temporal release pattern of copeptin and troponin T in patients with suspected acute coronary syndrome and spontaneous acute myocardial infarction. Clin Chem 61(10):1273–1282CrossRefPubMed

18.

Vafaie M, Slagman A, Möckel M et al (2016) Prognostic value of undetectable hs Troponin T in suspected acute coronary syndrome. Am J Med 129(3):274–282.e2CrossRefPubMed

19.

Montalescot G, van ’t Hof AW, Lapostolle F et al (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371(11):1016–1027CrossRefPubMed

20.

Möckel M (2023) Perspectives on cardiovascular biomarkers: one fits all biomarkers are out, personalization is in. Biomarkers 28(4):353CrossRefPubMed

21.

Möckel M (2020) One fits all hs troponin or more personalized dual markers strategies in the primary diagnostic assessment of patients with suspected acute coronary syndrome? Biomarkers 25(8):611–612CrossRefPubMed

22.

Möckel M (2022) Actual guidelines on non-ST-elevation acute coronary syndrome: how do they help in the emergency department? Eur J Emerg Med 29(1):2–4CrossRefPubMed

23.

Dörler J, Edlinger M, Alber HF et al (2011) Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J 32(23):2954–2961CrossRefPubMed

24.

Lapostolle F, Van’t Hof AW, Hamm CW et al (2019) Morphine and ticagrelor interaction in primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: ATLANTIC-morphine. Am J Cardiovasc Drugs 19(2):173–183CrossRefPubMed

25.

Desch S, Freund A, Akin I et al (2021) Angiography after out-of-hospital cardiac arrest without ST-segment elevation. N Engl J Med 385(27):2544–2553CrossRefPubMed

26.

Desch S, Freund A, Akin I et al (2023) Coronary angiography after out-of-hospital cardiac arrest without ST-segment elevation: one-year outcomes of a randomized clinical trial. JAMA Cardiol 8(9):827–834CrossRefPubMed

27.

Lemkes JS, Janssens GN, van der Hoeven NW et al (2019) Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J Med 380(15):1397–1407CrossRefPubMed

28.

Lemkes JS, Janssens GN, van der Hoeven NW et al (2020) Coronary angiography after cardiac arrest without ST segment elevation: one-year outcomes of the COACT randomized clinical trial. JAMA Cardiol 5(12):1358–1365CrossRefPubMed

29.

Hassager C, Schmidt H, Møller JE et al (2023) Duration of device-based fever prevention after cardiac arrest. N Engl J Med 388(10):888–897CrossRefPubMed

30.

Bharadwaj A, Potts J, Mohamed MO et al (2020) Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur Heart J 41(23):2183–2193CrossRefPubMed

Titel: The new ESC acute coronary syndrome guideline and its impact in the CPU and emergency department setting
verfasst von: Univ.-Prof. Dr. med. Martin Möckel, FESC, FAHA
Publikationsdatum: 11.03.2024
Verlag: Springer Medizin
Erschienen in: Herz
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-024-05241-6

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen